BioCentury
ARTICLE | Clinical News

AC-1204: Ph III NOURISH AD data

March 10, 2017 12:35 AM UTC

Top-line data from the double-blind, U.S. Phase III NOURISH AD trial in about 418 non-carriers of apolipoprotein E (APOE) epsilon 4 (APOE4) with mild to moderate AD showed that once-daily 40 g oral AC...

BCIQ Company Profiles

Cerecin Pte. Ltd.